Idvynso uniquely offers a two-drug, tenofovir-free, non-INSTI single-tablet regimen intended for switch in stable, suppressed ...
MedPage Today on MSN
FDA Approves New Standalone Combo Pill for HIV
Islatravir-doravirine matched alternate regimens in two phase III trials ...
FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard ...
Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...
HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...
The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).
INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...
Switching From HIV Protease Inhibitors to Integrase Strand Transfer Inhibitors Tied to Diabetes Risk
HealthDay News — Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV, according to a study published online March ...
† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results